COMMUNIQUÉS West-GlobeNewswire
-
Ligand to Acquire XOMA Royalty, Further Accelerating Profit Growth and Strengthening Ligand’s Position as a Leading Biopharma Royalty Aggregator
27/04/2026 -
Fulcrum Therapeutics Appoints Josh Lehrer to its Board of Directors
27/04/2026 -
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700
27/04/2026 -
Conference to focus on how artificial intelligence can dramatically reduce workplace injuries
27/04/2026 -
Every minute counts: EAACI calls for urgent action to make schools safe for children at risk of anaphylaxis
27/04/2026 -
Relay Therapeutics Announces Clinical Data for Zovegalisib plus Atirmociclib Triplet Combination Supportive of Further Development in Frontline Metastatic Breast Cancer
27/04/2026 -
KFSH Highlights Scalable AI Integration Model at C3 Davos of Healthcare™ Silicon Valley Summit
27/04/2026 -
Composition of the Nomination Committee of Orion Corporation
27/04/2026 -
Allarity Therapeutics Announces that the Stenoparib DRP® Test Has Received a Notice of Allowance from the US Patent and Trademark Office
27/04/2026 -
Evaxion promotes Birgitte Rønø to joint role of Chief Scientific and Chief Operating Officer
27/04/2026 -
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026
27/04/2026 -
Real-World Data on EXPAREL® Shows Reduced Opioid Use and Lower Total Medical Costs in Medicare Patients Undergoing Total Hip Arthroplasty
27/04/2026 -
LifeMD to Report First Quarter 2026 Financial Results on May 6
27/04/2026 -
Solésence, Inc. Announces Appointment of New Independent Director
27/04/2026 -
Clearmind Medicine Announces Evaluation of its Psychedelic-Based Treatment (MEAI) for Potential FDA Breakthrough Therapy Designation
27/04/2026 -
BriaCell Announces Six Clinical Data Presentations at ASCO 2026
27/04/2026 -
Medicus Pharma CEO meets with lawmakers on Energy & Commerce Committee on Capitol Hill
27/04/2026 -
Tovecimig Demonstrates Statistically Significant Benefit in COMPANION-002 Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer
27/04/2026 -
HCW Biologics Delivers a Major Update for its T-Cell Engager Program Revealing Mechanism of Action and Validating Tissue Factor as Target for Treatment of Solid Tumors
27/04/2026
Pages